JP2011021026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011021026A5 JP2011021026A5 JP2010211089A JP2010211089A JP2011021026A5 JP 2011021026 A5 JP2011021026 A5 JP 2011021026A5 JP 2010211089 A JP2010211089 A JP 2010211089A JP 2010211089 A JP2010211089 A JP 2010211089A JP 2011021026 A5 JP2011021026 A5 JP 2011021026A5
- Authority
- JP
- Japan
- Prior art keywords
- amphoteric
- liposomes
- liposome
- charge carriers
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cation lipids Chemical class 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 5
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims description 4
- 150000001982 diacylglycerols Chemical class 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims 27
- 239000002800 charge carrier Substances 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 3
- 125000002091 cationic group Chemical group 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- HKYPYRMYYCHDFR-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC.NCC(O)=O Chemical compound CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC.NCC(O)=O HKYPYRMYYCHDFR-UHFFFAOYSA-N 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 241001441550 Zeiformes Species 0.000 claims 1
- AVTXVDFKYBVTKR-DPAQBDIFSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] dihydrogen phosphate Chemical compound C1C=C2C[C@@H](OP(O)(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 AVTXVDFKYBVTKR-DPAQBDIFSA-N 0.000 claims 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 claims 1
- 239000002088 nanocapsule Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 150000001449 anionic compounds Chemical class 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10109897.9 | 2001-02-21 | ||
| DE10109897A DE10109897A1 (de) | 2001-02-21 | 2001-02-21 | Fakultativ kationische Liposomen und Verwendung dieser |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565572A Division JP2004525898A (ja) | 2001-02-21 | 2002-02-21 | 両性リポソーム及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013237869A Division JP2014031383A (ja) | 2001-02-21 | 2013-11-18 | 両性リポソーム及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011021026A JP2011021026A (ja) | 2011-02-03 |
| JP2011021026A5 true JP2011021026A5 (enExample) | 2012-06-07 |
| JP5480764B2 JP5480764B2 (ja) | 2014-04-23 |
Family
ID=7675950
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565572A Pending JP2004525898A (ja) | 2001-02-21 | 2002-02-21 | 両性リポソーム及びその使用 |
| JP2010211089A Expired - Fee Related JP5480764B2 (ja) | 2001-02-21 | 2010-09-21 | 両性リポソーム及びその使用 |
| JP2013237869A Pending JP2014031383A (ja) | 2001-02-21 | 2013-11-18 | 両性リポソーム及びその使用 |
| JP2014165961A Pending JP2014218520A (ja) | 2001-02-21 | 2014-08-18 | 両性リポソーム及びその使用 |
| JP2016001813A Pending JP2016104786A (ja) | 2001-02-21 | 2016-01-07 | 両性リポソーム及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565572A Pending JP2004525898A (ja) | 2001-02-21 | 2002-02-21 | 両性リポソーム及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013237869A Pending JP2014031383A (ja) | 2001-02-21 | 2013-11-18 | 両性リポソーム及びその使用 |
| JP2014165961A Pending JP2014218520A (ja) | 2001-02-21 | 2014-08-18 | 両性リポソーム及びその使用 |
| JP2016001813A Pending JP2016104786A (ja) | 2001-02-21 | 2016-01-07 | 両性リポソーム及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7371404B2 (enExample) |
| EP (1) | EP1363601B1 (enExample) |
| JP (5) | JP2004525898A (enExample) |
| CN (1) | CN1241549C (enExample) |
| AT (1) | ATE363893T1 (enExample) |
| AU (1) | AU2002234643B2 (enExample) |
| BR (1) | BRPI0207775B1 (enExample) |
| CA (1) | CA2438116C (enExample) |
| DE (2) | DE10109897A1 (enExample) |
| ES (1) | ES2289079T3 (enExample) |
| WO (1) | WO2002066012A2 (enExample) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10109897A1 (de) * | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| DE10207177A1 (de) * | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
| US7858117B2 (en) * | 2002-02-21 | 2010-12-28 | Novosom Ag | Amphoteric liposomes and their use |
| CA2487274A1 (en) * | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| DE10255106A1 (de) * | 2002-11-24 | 2004-06-09 | Novosom Ag | Liposomale Glucocorticoide |
| EP1547580A1 (en) * | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Loading of a camptothecin drug into colloidal nanoparticles |
| DE102004054730A1 (de) | 2004-03-28 | 2006-05-11 | Novosom Ag | Serumstabile amphotere Liposomen |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| AU2005300638A1 (en) * | 2004-11-05 | 2006-05-11 | Novosom Ag | Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent |
| EP1764090A1 (en) * | 2005-09-15 | 2007-03-21 | Novosom AG | Amphoteric liposomes for local drug applications |
| EP1811960A2 (en) * | 2004-11-19 | 2007-08-01 | Novosom AG | Improvements in or relating to pharmaceutical compositions for local administration |
| EP1676569A1 (en) * | 2004-12-30 | 2006-07-05 | Pevion Biotech Ltd. | Lyophilization of virosomes |
| EP1764091B1 (en) * | 2005-09-15 | 2017-08-30 | Marina Biotech, Inc. | Improvements in or relating to amphoteric liposomes |
| US20120021042A1 (en) * | 2005-09-15 | 2012-01-26 | Steffen Panzner | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances |
| US20080088046A1 (en) * | 2006-10-13 | 2008-04-17 | Steffen Panzner | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome |
| EP1911443A1 (en) * | 2006-10-13 | 2008-04-16 | Novosom AG | Amphoteric liposomes, method of formulating an amphoteric liposome and a method of loading an amphoteric liposome |
| EP1764089A1 (en) * | 2005-09-15 | 2007-03-21 | Novosom AG | Serum stable liposomes comprising amphoter II lipid mixtures |
| EP1934348B1 (en) * | 2005-10-11 | 2018-05-02 | Ben-Gurion University Of The Negev Research And Development Authority | Compositions for silencing the expression of vdac1 and uses thereof |
| US20090324587A1 (en) | 2005-12-01 | 2009-12-31 | Neal Clifford Goodwin | Cancer Therapies and Pharmaceutical Compositions Used Therein |
| JP5122474B2 (ja) * | 2005-12-01 | 2013-01-16 | プロネイ・セラピューティクス・インコーポレイテッド | 両性リポソーム製剤 |
| ES2798263T3 (es) | 2005-12-08 | 2020-12-10 | Insmed Inc | Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares |
| WO2007117550A2 (en) * | 2006-04-06 | 2007-10-18 | Transave, Inc. | Methods for coacervation induced liposomal encapsulation and formulations thereof |
| US20140178462A1 (en) * | 2006-10-13 | 2014-06-26 | Marina Biotech, Inc. | Amphoteric liposomes comprising neutral lipids |
| AU2007306556B2 (en) * | 2006-10-13 | 2014-04-10 | Marina Biotech, Inc. | Improvements in or relating to amphoteric liposomes |
| JP2010513354A (ja) * | 2006-12-19 | 2010-04-30 | ノヴォソム アクチェンゲゼルシャフト | トランスフェクションエンハンサー要素を含む脂質および脂質集合体 |
| WO2008118013A2 (en) | 2007-03-23 | 2008-10-02 | To-Bbb Holding B.V. | Targeted intracellular delivery of antiviral agents |
| US20080260895A1 (en) * | 2007-04-17 | 2008-10-23 | Vermeire Drew A | Milk replacer composition and product and method for producing the same |
| WO2008137717A1 (en) | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
| EP3434259A1 (en) | 2007-05-04 | 2019-01-30 | Marina Biotech, Inc. | Amino acid lipids and uses thereof |
| US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| DE102007029471A1 (de) | 2007-06-20 | 2008-12-24 | Novosom Ag | Neue fakultativ kationische Sterole |
| WO2008154700A1 (en) | 2007-06-20 | 2008-12-24 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith |
| EP2200586B1 (en) * | 2007-09-07 | 2019-11-13 | Synvolux IP B.V. | Improved liposomes and uses thereof |
| CA2702103A1 (en) * | 2007-10-12 | 2009-04-16 | Novosom Ag | Improvements in or relating to amphotaric liposomes comprising neutral lipids |
| WO2009149418A2 (en) * | 2008-06-06 | 2009-12-10 | Asuragen, Inc. | Novel compositions for the in vivo delivery of rnai agents |
| CN104382853A (zh) | 2008-10-16 | 2015-03-04 | 玛瑞纳生物技术有限公司 | 基因沉默治疗剂的脂质体有效递送方法和组合物 |
| JP5392707B2 (ja) * | 2009-03-31 | 2014-01-22 | 株式会社Ｎｔｔドコモ | 膜小胞分裂システム |
| US20120107389A1 (en) * | 2009-03-31 | 2012-05-03 | Jayanta Bhattacharyya | Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference |
| WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
| ES2386855T3 (es) * | 2009-07-09 | 2012-09-03 | Marina Biotech, Inc. | Emulación de estructuras de lipoproteínas |
| AU2010270337B2 (en) | 2009-07-09 | 2016-09-22 | Biontech Delivery Technologies Gmbh | Amphoteric liposomes comprising imino lipids |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| WO2011120023A1 (en) | 2010-03-26 | 2011-09-29 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting survivin gene expression uses thereof |
| WO2011133584A2 (en) | 2010-04-19 | 2011-10-27 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting hras gene expression and uses thereof |
| WO2011139842A2 (en) | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2012159164A1 (en) | 2011-05-23 | 2012-11-29 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| CN102532259A (zh) * | 2012-03-09 | 2012-07-04 | 中国药科大学 | 基于寡肽的阳离子脂质衍生物及在药剂制剂中的应用 |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| CN102603866B (zh) * | 2012-03-15 | 2014-01-15 | 中国药科大学 | 基于寡肽的pH敏感型两性离子及其在药剂中的应用 |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| PL2852391T3 (pl) | 2012-05-21 | 2022-04-11 | Insmed Incorporated | Układy do leczenia infekcji płuc |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| WO2013186793A1 (en) * | 2012-06-11 | 2013-12-19 | Council Of Scientific & Industrial Research | Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells |
| AU2013340414B2 (en) | 2012-10-23 | 2019-05-02 | Caris Science, Inc. | Aptamers and uses thereof |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| CN104884637A (zh) | 2012-11-05 | 2015-09-02 | 普隆奈治疗公司 | 利用生物标志物通过bcl2表达的调节治疗癌症的方法 |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| CA2891487A1 (en) | 2012-11-29 | 2014-06-05 | Insmed Incorporated | Stabilized vancomycin formulations |
| AU2013361323B2 (en) | 2012-12-19 | 2018-09-06 | Caris Science, Inc. | Compositions and methods for aptamer screening |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| KR102311614B1 (ko) | 2013-03-14 | 2021-10-08 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| WO2014143855A2 (en) | 2013-03-15 | 2014-09-18 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing micrornas and egfr-tki inhibitors |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| JP2016530232A (ja) | 2013-06-24 | 2016-09-29 | ミルナ セラピューティクス，インク． | Ｍｉｒ−３４活性のバイオマーカー |
| JP5914418B2 (ja) | 2013-06-26 | 2016-05-11 | 富士フイルム株式会社 | 脂質粒子、核酸送達キャリア、核酸送達キャリア製造用組成物、脂質粒子の製造方法及び遺伝子導入方法 |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| EP3126496A1 (en) | 2014-04-01 | 2017-02-08 | Mirna Therapeutics, Inc. | Microrna dosing regimens |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| EP4729528A3 (en) | 2014-04-25 | 2026-06-24 | Translate Bio, Inc. | Methods for purification of messenger rna |
| MX384843B (es) | 2014-05-15 | 2025-03-14 | Insmed Inc | Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas. |
| JP6240570B2 (ja) | 2014-07-17 | 2017-11-29 | 富士フイルム株式会社 | 脂質粒子および核酸送達キャリア |
| US10722599B2 (en) | 2015-02-04 | 2020-07-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Lipid assemblies and uses thereof and some pH and electrostatic modulating lipids to be used in said assemblies |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| IL270631B2 (en) | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| KR20200050982A (ko) * | 2017-09-04 | 2020-05-12 | 이치마루 화루코스 가부시키가이샤 | pH 감수성 리포솜 및 그 제조 방법 |
| WO2019048645A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE |
| HRP20260181T1 (hr) * | 2017-10-20 | 2026-03-27 | BioNTech SE | Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju |
| TW201936201A (zh) | 2017-12-14 | 2019-09-16 | 美商堅固生物科技公司 | 基因之非病毒生產及遞送 |
| EP3773505B1 (en) | 2018-03-30 | 2026-04-29 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| US11566246B2 (en) | 2018-04-12 | 2023-01-31 | Mina Therapeutics Limited | SIRT1-saRNA compositions and methods of use |
| EP3787602A4 (en) | 2018-05-02 | 2022-03-23 | Insmed Incorporated | PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS |
| US20190381034A1 (en) * | 2018-06-14 | 2019-12-19 | Ming Fang | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases |
| US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| CA3110661A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| EP3953473A1 (en) | 2019-04-12 | 2022-02-16 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| AU2020351220A1 (en) | 2019-09-19 | 2022-04-07 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP4031524A1 (en) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| CA3155003A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| US12115230B2 (en) | 2020-04-09 | 2024-10-15 | Verve Therapeutics, Inc. | Base editing of ANGPTL3 and methods of using same for treatment of disease |
| WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
| WO2022060871A1 (en) | 2020-09-15 | 2022-03-24 | Verve Therapeutics, Inc. | Lipid formulations for gene editing |
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| EP4015634A1 (en) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| US20240175033A1 (en) | 2021-03-26 | 2024-05-30 | Mina Therapeutics Limited | TMEM173 saRNA Compositions and Methods of Use |
| WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
| GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
| TW202440929A (zh) | 2022-12-14 | 2024-10-16 | 加拿大商普羅維登斯治療控股公司 | 用於感染性疾病的組合物和方法 |
| US20260218178A1 (en) | 2022-12-22 | 2026-07-30 | Mina Therapeutics Limited | Chemically Modified saRNA Compositions and Methods of Use |
| IL321425A (en) | 2022-12-23 | 2025-08-01 | Biontech Delivery Tech Gmbh | compound |
| KR20260065891A (ko) | 2023-09-01 | 2026-05-11 | 노보아크 게엠베하 | 핵산 카고 및 이온화가능한 지질을 갖는 지질 나노입자 |
| CN122535391A (zh) * | 2023-12-22 | 2026-08-07 | 科蒂公司 | 用于将功能剂递送到皮肤的阳离子微囊泡和功能化外泌体样载体 |
| WO2026027887A2 (en) | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599227A (en) * | 1983-11-07 | 1986-07-08 | Wisconsin Alumni Research Foundation | Injectable pharmaceutical preparation for the induction of multiple follicular growth |
| US4891208A (en) | 1985-04-10 | 1990-01-02 | The Liposome Company, Inc. | Steroidal liposomes |
| US5283122A (en) * | 1984-04-19 | 1994-02-01 | University Of Tennessee Research Corporation | Fused liposome and acid induced method for liposome fusion |
| ATE45744T1 (de) | 1984-07-25 | 1989-09-15 | Ciba Geigy Ag | Phosphatidylverbindungen, verfahren zu ihrer herstellung und ihre verwendung. |
| US5077211A (en) * | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5290563A (en) * | 1989-07-27 | 1994-03-01 | Laboratoire Des Stallergenes | Method for combining a mixture of heterogeneous substances with liposomes |
| US5165994A (en) | 1990-06-05 | 1992-11-24 | University Of Delaware | Spontaneous equilbrium surfactant vesicles |
| US5302389A (en) * | 1992-08-17 | 1994-04-12 | Board Of Regents, The University Of Texas System | Method for treating UV-induced suppression of contact hypersensitivity by administration of T4 endonuclease |
| JP2950520B2 (ja) * | 1993-04-02 | 1999-09-20 | アンティキャンサー インコーポレーテド | 毛胞に有益な配合物を送達する方法 |
| US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
| US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US6258792B1 (en) * | 1996-04-12 | 2001-07-10 | University Of Pittsburgh | Cationic cholesteryl derivatives containing cyclic polar groups |
| ES2165050T3 (es) * | 1996-04-12 | 2002-03-01 | Univ Pittsburgh | Nuevos derivados cationicos de colesterilo que contienen grupos polares ciclicos. |
| EP0938298B1 (en) * | 1996-09-13 | 2002-12-04 | Lipoxen Technologies Limited | Liposome-based composition |
| US7384923B2 (en) * | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
| US5962015A (en) * | 1997-05-02 | 1999-10-05 | Kobo Products S.A.R.L. | Stabilized liposomes |
| CA2289702C (en) * | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| AU8525098A (en) * | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| FR2766706B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation |
| US6106858A (en) * | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
| JPH11302199A (ja) * | 1998-04-16 | 1999-11-02 | Sankyo Co Ltd | 薬物運搬体を構成するグラフト共重合体 |
| JP2000198731A (ja) * | 1998-10-29 | 2000-07-18 | Sankyo Co Ltd | 毒性の低減されたリポソ―ム |
| DE19852928C1 (de) | 1998-11-17 | 2000-08-03 | Steffen Panzner | Strukturen in Form von Hohlkugeln |
| US6379698B1 (en) * | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
| DE10010264A1 (de) | 2000-03-02 | 2001-09-13 | Novosom Gmbh | Stabilisierte Liposomen und Hüllstrukturen |
| DE10109897A1 (de) * | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| US7858117B2 (en) * | 2002-02-21 | 2010-12-28 | Novosom Ag | Amphoteric liposomes and their use |
| EP1764091B1 (en) * | 2005-09-15 | 2017-08-30 | Marina Biotech, Inc. | Improvements in or relating to amphoteric liposomes |
-
2001
- 2001-02-21 DE DE10109897A patent/DE10109897A1/de not_active Withdrawn
-
2002
- 2002-02-21 BR BRPI0207775A patent/BRPI0207775B1/pt not_active IP Right Cessation
- 2002-02-21 EP EP02701290A patent/EP1363601B1/de not_active Expired - Lifetime
- 2002-02-21 ES ES02701290T patent/ES2289079T3/es not_active Expired - Lifetime
- 2002-02-21 CA CA2438116A patent/CA2438116C/en not_active Expired - Lifetime
- 2002-02-21 JP JP2002565572A patent/JP2004525898A/ja active Pending
- 2002-02-21 DE DE50210271T patent/DE50210271D1/de not_active Expired - Lifetime
- 2002-02-21 US US10/081,617 patent/US7371404B2/en not_active Expired - Lifetime
- 2002-02-21 WO PCT/EP2002/001880 patent/WO2002066012A2/de not_active Ceased
- 2002-02-21 AT AT02701290T patent/ATE363893T1/de active
- 2002-02-21 CN CNB028052137A patent/CN1241549C/zh not_active Expired - Fee Related
- 2002-02-21 AU AU2002234643A patent/AU2002234643B2/en not_active Ceased
-
2006
- 2006-10-31 US US11/590,143 patent/US20070269504A1/en not_active Abandoned
- 2006-10-31 US US11/590,357 patent/US7780983B2/en not_active Expired - Lifetime
-
2010
- 2010-08-09 US US12/806,342 patent/US20110293695A1/en not_active Abandoned
- 2010-09-21 JP JP2010211089A patent/JP5480764B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-18 JP JP2013237869A patent/JP2014031383A/ja active Pending
-
2014
- 2014-08-18 JP JP2014165961A patent/JP2014218520A/ja active Pending
-
2016
- 2016-01-07 JP JP2016001813A patent/JP2016104786A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014218520A5 (enExample) | ||
| Li et al. | A review on phospholipids and their main applications in drug delivery systems | |
| JP5424885B2 (ja) | 両性リポソームにおけるまたは両性リポソームに関する改善、両性リポソームを処方する方法および両性リポソームに充填する方法 | |
| WO2007031333A3 (en) | Improvements in or relating to amphoteric liposomes | |
| Hafez et al. | Roles of lipid polymorphism in intracellular delivery | |
| US7780983B2 (en) | Amphoteric liposomes | |
| RU2017113970A (ru) | Стабильные составы липидов и липосом | |
| US7858117B2 (en) | Amphoteric liposomes and their use | |
| Koynova et al. | Cationic phospholipids: structure–transfection activity relationships | |
| JP5796113B2 (ja) | トランスフェクションエンハンサー要素を含む脂質および脂質集合体 | |
| ban Duijn et al. | Dolichyl phosphate induces non-bilayer structures, vesicle fusion and transbilayer movement of lipids: a model membrane study | |
| JP2016505545A5 (enExample) | ||
| JP2005526727A5 (enExample) | ||
| JP2020532546A5 (enExample) | ||
| JP2015110625A (ja) | 中性脂質を含む両性リポソーム | |
| US20240209397A1 (en) | Thermally Stable Lipid-Nucleic Acid Molecule Formulations Utilising Metal Organic Framework (MOF) Shells | |
| KR20110114202A (ko) | 경피흡수용 고분자-리포좀 나노복합체 조성물 및 그 제조방법 | |
| Goldberg et al. | Effects of dipalmitoylglycerol and fatty acids on membrane structure and protein kinase C activity | |
| CA2933001A1 (en) | Siloxane-containing phospholipids, compositions and uses thereof | |
| US20080088046A1 (en) | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome | |
| Smaal et al. | Calcium-induced changes in permeability of dioleoylphosphatidylcholine model membranes containing bovine heart cardiolipin | |
| Ishiyama et al. | The formation of helical tubular vesicles by binary monolayers containing a nickel-chelating lipid and phosphoinositides in the presence of basic polypeptides | |
| EP1847315A1 (en) | Method for coating particle with lipid film | |
| Mora et al. | Aggregation and fusion of vesicles composed of N-palmitoyl derivatives of membrane phospholipids | |
| JP4787818B2 (ja) | 脱水縮合反応により相転移を生じ得る分子集合体およびその相転移方法 |